ABCL AbCellera Biologics Inc.Stock Price & Overview
$3.78
Charts
Quant Ranking
ABCL Analysis
ABCL News
Latest Headlines
Ratings Summary
ABCL Company Profile
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL Revenue
ABCL Earnings Per Share
Earnings Estimates
Earnings Revisions
Rating:
Valuation
Rating:
Growth
Rating:
Profitability
Rating:
Momentum
Rating:
52 Week Range
Capital Structure
Trading Data
Dividends
ABCL Ownership
ABCL Peers
Risk
Technicals
ABCL Transcripts
Investor Presentations
ABCL SEC Filings
Press Releases
ABCL Income Statement
ABCL Balance Sheet
ABCL Cash Flow Statement
ABCL Long Term Solvency
Discover More
You may be interested in: